REFERENCES
- Boolell M, Gepi-Attee S, Gingell J C, Allen M J. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257–261
- Goldstein L, Lue T F, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–1404
- Stief C G, Uckert S, Becker A J, et al. The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo. J Urol 1998; 159: 1390–1393
- Carter A J, Ballard S A, Naylor A M. Effect of the selective phosphodiesterase type 5 inhibitor sildenafil on erectile function in the anesthetized dog. J Urol 1998; 160: 242–246
- Chuang A T, Strauss J D, Murphy R A, Steers W D. Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol 1998; 160: 257–261
- Jeremy J Y, Ballard S A, Naylor A M, Miller N A, Angelini G D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in rabbit corpus cavernosum in vitro. Br J Urol 1997; 79: 958–963
- Park K, Moreland R B, Goldstein I, Atala A, Traish A. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Comm 1998; 249: 612–617
- Jackson G, Benjamin N, Jackson N, et al. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83: 13C–20C
- Boolell M, Allen M J, Ballard S A, et al. Sildenafil: An oral active type 5 cyclic GMP phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52
- Ballard S A, Gingell C J, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isoenzymes. J Urol 1998; 159: 2164–2171
- de May C. Opportunities for the treatment of erectile dysfunction by modulation of the NO axis—Alternatives to sildenafil citrate. Curr Med Res Opinion 1998; 14: 187–202
- Cheitlin M D, Hutter A M, Brindis R G, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. ACC/AHA Expert Consensus Document. Circulation 1999; 99: 168–177
- Naylor A M. Endogenous neurotransmitters mediating penile erection. Br J Urol 1998; 81: 424–431
- Goldenberg M M. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 1998; 20: 1033–1048
- Aldridge J, Measham F. Sildenafil (Viagra) is used as a recreational drug in England. Br Med J 1999; 318: 669–670
- Arora R R, Timoney M, Melilli L. Acute myocardial infarction after the use of sildenafil. N Engl J Med 1999; 341: 700–701
- Feenstra J, Van Drie-Pierik R J, Lacle C F, Stricker B H. Acute myocardial infarction associated with sildenafil. Lancet 1998; 352: 957–958
- Lopez-Lazaro L, Gracia Arenillas M, Perez-Portoles A, Vargas-Castrillon E, Moreno-Gonzalez A. Acute myocardial infarction associated with sildenafil. Lancet 1998; 352: 1936–1937
- Martinez F, Maillet R, Legendre C, Buisson C. Acute myocardial infarction associated with sildenafil. Lancet 1998; 32: 1937
- Hall M CS, Ahmad S. Interaction between sildenafil and HIV-1 combination therapy. Lancet 1999; 353: 2071–2072
- Lotovitz R L, Klein-Schwartz W, Caravati E M, et al. 1998 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 1999; 17: 435–487
- Morales A, Gingell C, Collins M, Wicker P A, Osterloh I H. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–74